Table 2. Correlation of human... | American Society of Hematology

Table 2.

Correlation of human cytomegalovirus (HCMV) infection and HCMV-specific immune reconstitution in patients after allogeneic stem cell transplantation (SCT)

Patient	Donor	HLA alleles	Acute GVHD	Steroids (mg/kg)^*	HCMV infection before day 100 after SCT^†			HCMV disease	Peptide-specific CD8⁺^‡		Protein-specific CD4⁺^2-154
Patient	Donor	HLA alleles	Acute GVHD	Steroids (mg/kg)^*	Duration, wk	Day last positive PCR	Peak viral load (GE/mL)	HCMV disease	Day first detected^2-153	Peak count (n/μL)	Day first detected^2-153	Peak count (n/μL)
Group 1 (donor positive for HCMV)
1	Sibl	A2, B7	II	2	0	—	—	—	+ 35 (A2)	1.01	+ 35	SI positive
2	Sibl	A2	0	0	3	+ 35	3610	—	+ 38	23.2	+ 38	18.97
3	Sibl	A3, B35	II	2	2	+ 84	2960	—	> 120	—	> 120	—
4	Sibl	B35	II	10	0	—	—	—	> 120	—	> 120	—
5^2-159	Sibl	A1, A2, B44	II	2	3	+ 221	3240	—	+ 234 (A2)	9.7	ND	—
6	Sibl	A11	0	0	6	+ 63	46 100	—	> 180	—	> 180	—
7^2-160	Sibl	A1	0	—	6	+ 71	ND	—	+ 90	10.38	+ 90	3.42
8^2-160	MM	A1	III	2	4	> 100	5590	Late retinitis	+ 95	5.47	> 120	—
9^2-160	MM	B7	I	2	2	+ 57	2980	—	+ 66	7.95	+ 66	2.13
10^2-160	MM	A2, A24	II	2	9	+ 139	ND	—	+ 120 (A2)	60.6	+ 120	1.09
11	MM	A2, B7	III	10	0	—	—	—	+ 61 (B7)	0.14	+ 61	SI positive
12	MM	A3, B35	II	7.5	3	+ 76	4580	—	+ 70 (B35)	3.52	+ 140	0.64
13	MUD	B44	0	0	2	+ 44	1950	—	+ 60	2.21	+ 60	9.22
14^2-159	MUD	A1	I	2	3	+ 36	1520	—	+ 35	26.45	+ 63	5.6
15^2-159	MUD	A2	II	10	2	+ 75	ND	Late IP	+ 85	37.96	> 85	—
Group 2 (donor negative for HCMV)
16	Sibl	A1	I	—	1	+ 43	ND	—	+ 60 (A1)	2.37	+ 60	5.77
17	MUD	A1, A2	0	1	12	+ 230	210 000	—	> 150	—	> 150	—
18	MUD	A3, A24	II	1	0	—	—	—	> 120	—	> 120	—
19^2-159	MUD	A1, A3, B7	0	3	1	+ 92	2640	—	+ 90 (A1, B7)	6.8	+ 90	1.02

Patient	Donor	HLA alleles	Acute GVHD	Steroids (mg/kg)^*	HCMV infection before day 100 after SCT^†			HCMV disease	Peptide-specific CD8⁺^‡		Protein-specific CD4⁺^2-154
Patient	Donor	HLA alleles	Acute GVHD	Steroids (mg/kg)^*	Duration, wk	Day last positive PCR	Peak viral load (GE/mL)	HCMV disease	Day first detected^2-153	Peak count (n/μL)	Day first detected^2-153	Peak count (n/μL)
Group 1 (donor positive for HCMV)
1	Sibl	A2, B7	II	2	0	—	—	—	+ 35 (A2)	1.01	+ 35	SI positive
2	Sibl	A2	0	0	3	+ 35	3610	—	+ 38	23.2	+ 38	18.97
3	Sibl	A3, B35	II	2	2	+ 84	2960	—	> 120	—	> 120	—
4	Sibl	B35	II	10	0	—	—	—	> 120	—	> 120	—
5^2-159	Sibl	A1, A2, B44	II	2	3	+ 221	3240	—	+ 234 (A2)	9.7	ND	—
6	Sibl	A11	0	0	6	+ 63	46 100	—	> 180	—	> 180	—
7^2-160	Sibl	A1	0	—	6	+ 71	ND	—	+ 90	10.38	+ 90	3.42
8^2-160	MM	A1	III	2	4	> 100	5590	Late retinitis	+ 95	5.47	> 120	—
9^2-160	MM	B7	I	2	2	+ 57	2980	—	+ 66	7.95	+ 66	2.13
10^2-160	MM	A2, A24	II	2	9	+ 139	ND	—	+ 120 (A2)	60.6	+ 120	1.09
11	MM	A2, B7	III	10	0	—	—	—	+ 61 (B7)	0.14	+ 61	SI positive
12	MM	A3, B35	II	7.5	3	+ 76	4580	—	+ 70 (B35)	3.52	+ 140	0.64
13	MUD	B44	0	0	2	+ 44	1950	—	+ 60	2.21	+ 60	9.22
14^2-159	MUD	A1	I	2	3	+ 36	1520	—	+ 35	26.45	+ 63	5.6
15^2-159	MUD	A2	II	10	2	+ 75	ND	Late IP	+ 85	37.96	> 85	—
Group 2 (donor negative for HCMV)
16	Sibl	A1	I	—	1	+ 43	ND	—	+ 60 (A1)	2.37	+ 60	5.77
17	MUD	A1, A2	0	1	12	+ 230	210 000	—	> 150	—	> 150	—
18	MUD	A3, A24	II	1	0	—	—	—	> 120	—	> 120	—
19^2-159	MUD	A1, A3, B7	0	3	1	+ 92	2640	—	+ 90 (A1, B7)	6.8	+ 90	1.02

GVHD indicates acute graft-versus-host disease; PCR, polymerase chain reaction assay; GE, genome equivalents; Sibl, HLA-identical sibling; SI, stimulation index; MM, HLA-nonidentical family member; MUD, matched unrelated donor; IP, interstitial pneumonia; and ND, not done.

Peak steroid dose.

†

Duration indicates the weeks of viremia as assessed by the in-house PCR method before day 100 after SCT. Viral load was measured with a COBAS Amplicor HCMV monitor. The peak viral load before day 100 is indicated.

‡

The HLA restriction of HCMV-peptide-specific cytotoxic T lymphocytes is indicated in parentheses.

F2-153

Values are the first day after SCT that T-cell reactivities were observed.

F2-154

T-cell responses were assessed by intracellular interferon-γ staining, lymphoproliferation (SI), or both.

F2-160

Patients who received CD34⁺-selected stem cells obtained with use of the CliniMACS system.

F2-159

Patients who received nonmyeloablative conditioning treatment.

View Large

This Feature Is Available To Subscribers Only